Filters
Other countries
| Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
|---|---|---|---|
Centogene AG - the Rare Disease Company Germany | 1886 | 1858 |
|
Centogene AG - the Rare Disease Company Germany | 406 | 414 |
|
Centogene AG - the Rare Disease Company Germany | 78 | 76 |
|
Invitae Nuclear Mitochondrial Disorders Panel Labcorp Genetics (formerly Invitae) LabCorp United States | 394 | 319 |
|
Invitae Hereditary Parkinson Disease and Parkinsonism Panel Labcorp Genetics (formerly Invitae) LabCorp United States | 44 | 26 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Parkinson Disease and Parkinsonism Panel PreventionGenetics, part of Exact Sciences United States | 70 | 71 |
|
PreventionGenetics, part of Exact Sciences United States | 27 | 24 |
|
Parkinson's Disease, Early Onset via the PINK1 Gene PreventionGenetics, part of Exact Sciences United States | 1 | 1 |
|
Institute for Human Genetics University Medical Center Freiburg Germany | 1 | 1 |
|
Parkinson's disease panel. NGS panel of 22 genes. Genologica Medica Spain | 45 | 22 |
|
Parkinson deletion/duplication analysis Duzen Laboratories Duzen BBAGUAS Turkey | 8 | 8 |
|
Duzen Laboratories Duzen BBAGUAS Turkey | 1 | 1 |
|
Retinopathy and Optic Atrophy NGS Panel Fulgent Genetics United States | 563 | 241 |
|
Adolescent/Adult Epilepsy NGS Panel Fulgent Genetics United States | 182 | 82 |
|
PINK1 Type of Young-Onset Parkinson Disease: gene deletion/duplication CEN4GEN Institute for Genomics and Molecular Diagnostics Canada | 1 | 1 |
|
PINK1 Type of Young-Onset Parkinson Disease: gene sequencing CEN4GEN Institute for Genomics and Molecular Diagnostics Canada | 1 | 1 |
|
Parkinson Disease: Full gene sequencing panel CEN4GEN Institute for Genomics and Molecular Diagnostics Canada | 20 | 24 |
|
Laboratorio de Genetica Clinica SL Spain | 1 | 0 |
|
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.